CVS Health Corp Earnings - Q2 2026 Analysis & Highlights
CVS Health delivered strong Q2 2026 results with broad-based growth across all operating segments, raised full-year guidance, and emphasized strategic investments in technology and AI while navigating near-term headwinds in its pharmacy services business.
Key Financial Results
Total revenue of over $106 billion, representing an increase of over 7% year-over-year.
Adjusted operating income of approximately $5.2 billion, an increase of 35% year-over-year.
Adjusted earnings per share (EPS) of $2.58, a significant increase of over 40% year-over-year.
Year-to-date cash flow from operations of approximately $10.6 billion.
Leverage ratio at quarter end of approximately 3.5 times.
Business Segment Results
Health Care Benefits segment revenue of over $37 billion, an increase of over 3% year-over-year, primarily driven by the Government business.
Health Care Benefits adjusted operating income of approximately $2.4 billion, with a medical benefit ratio (MBR) of 87.4%, both improving meaningfully from the prior year quarter.
Health Care Benefits medical membership of approximately 26 million members at quarter end, remaining consistent sequentially but declining approximately 700,000 members year-over-year, primarily due to exit from the individual exchange business.
Health Services segment revenues of nearly $52 billion, an increase of over 11% year-over-year, primarily driven by pharmacy drug mix and brand inflation.
Health Services adjusted operating income of over $1.7 billion, an increase of 10% year-over-year, primarily driven by improved purchasing economics and pharmacy drug mix.
Pharmacy & Consumer Wellness segment revenues of nearly $34 billion, a slight increase from the prior year quarter, driven by pharmacy drug mix, increased prescription volume including Rite Aid transaction contributions, and brand inflation.
Pharmacy & Consumer Wellness adjusted operating income of nearly $1.5 billion, an increase of over 10% year-over-year, primarily driven by core pharmacy strength and Rite Aid contributions.
Same-store pharmacy sales growth of approximately 3%, driven by a 7% increase in same-store prescription volumes.
Same-store front store sales increased 100 basis points versus the prior year quarter.
Health Care Delivery business revenues grew nearly 23% compared to the same quarter last year, primarily driven by Oak Street Health.
Capital Allocation
Shareholder dividends of over $1.7 billion returned year-to-date.
Current guidance does not assume any share repurchases this year, with the company continuing to evaluate capital deployment opportunities as leverage position improves.
Cash at the parent and unrestricted subsidiaries of approximately $2.7 billion at quarter end.
Industry Trends and Dynamics
GLP-1 therapies for weight loss represent a significant growth opportunity, with consumers increasingly focused on affordability, access, and convenience.
Demand for GLP-1 therapies continues to grow, with consumers seeking access both through traditional benefit designs and direct-to-consumer pathways.
340B program environment remains dynamic, with pharmaceutical manufacturers imposing restrictions on covered entities that led to pressure in the second quarter.
Specialty drugs becoming generic create pressure in the 340B program.
Elevated medical cost trends continue, with the company maintaining a respectful and prudent view of medical cost trends in the second half of the year.
Independent Dispute Resolution (IDR) process under the No Surprises Act is being abused by a small group of players, creating cost pressures not playing out as intended.
Competitive Landscape
CVS Health positioned as a leader in GLP-1 affordability, access, and convenience, with comprehensive direct-to-consumer platform capabilities.
MinuteClinic's 24/7 virtual weight management offering is the lowest cost option in the industry at $29 per visit.
CVS Specialty is the most tech-enabled specialty pharmacy in the industry, with adherence rates consistently operating above 90%, while others in the industry work towards achieving 80% adherence.
CVS Pharmacy established as the best-run national pharmacy in the country through deliberate actions and intentional investments.
Aetna has an industry-leading team in place with deliberate, coordinated actions improving both results and positioning.
Caremark leads the industry in taking formulary actions to increase availability of GLP-1 drugs at lower cost.
Macroeconomic Environment
Challenging macro environment noted with front store sales growth of 100 basis points despite headwinds.
High brand inflation continues across the pharmacy industry.
Elevated medical cost trends persist in the commercial business, with the company pricing for elevated trends seen in 2024.
Growth Opportunities and Strategies
GLP-1 market expansion through multiple channels including Caremark formulary management, MinuteClinic virtual offerings, and partnerships with Eli Lilly and Novo for direct-to-consumer access.
Health100 platform and Haio AI-powered assistant launch designed to simplify consumer experience and help people engage more effectively in their care journey, with early feedback encouraging.
AI-enabled Claims Assist Manager reducing processing time by over 20% and accelerating payment for providers on hundreds of millions of claims annually.
Aetna Clinical Collaboration program expansion, embedding nurses directly into facilities to work alongside hospital staff during critical care transitions.
Technology infrastructure modernization in Care Delivery business to accelerate data sharing and connectivity with providers and payer partners.
AI and analytics deployment to reduce provider administration burden, with analysis of over 1 billion pages of clinical records to enable personalized and coordinated care.
CVS CostVantage cost-based pricing model driving more sustainable pharmacy reimbursement and helping align with payers on value creation.
Cordavis biosimilar launch generating over $1.8 billion of savings on Humira for customers.
$20-plus-billion commitment to technology investments over the next decade, with deliberate and responsible deployment focused on appropriate ROI and use cases.
Over $1 billion in OpEx savings generated over the last few years through technology efficiencies and AI.
Financial Guidance and Outlook
Full year 2026 adjusted EPS guidance raised to a range of $7.90 to $8.10, an increase of $0.60 or 8% higher than previous guidance.
Full year total revenues expected to be at least $414 billion.
Health Care Benefits segment full year adjusted operating income expected in a range of $5.03 billion to $5.37 billion, an increase of over $1 billion relative to prior guidance.
Full year MBR expected to be 89.75%, plus or minus 25 basis points.
Pharmacy & Consumer Wellness segment full year adjusted operating income expected to be at least $6.4 billion, an increase of $220 million from prior guidance.
Full year enterprise adjusted operating income expected in the range of $16.58 billion to $16.92 billion.
Full year cash flow from operations expected to be at least $11.5 billion, reflecting updated earnings outlook and working capital improvements.
Second half EPS expected to be more weighted to the third quarter, reflecting typical seasonality.
Increase between first quarter and fourth quarter MBR expected to be slightly higher than 950 basis points after adjusting for prior year development impact in the first quarter.
Mid-teens adjusted EPS CAGR from 2025 through 2028 remains the company's confidence level.
2027 adjusted EPS floor of at least $8.44, consistent with current consensus, representing EPS growth of about 13% off an adjusted baseline of $7.46.
2027 headwinds expected in Pharmacy Services business including continued 340B pressure and membership declines in Caremark due to disciplined approach to client renewals and health plan customer product actions.
2027 tailwinds expected from specialty pharmacy business continuing to benefit from strong execution and secular trends, including a robust generic portfolio.
Health Care Delivery business expected to remain on track driving improved results in 2027.
Pharmacy & Consumer Wellness business building strong momentum with second consecutive year of mid-single-digit growth reflected in updated guidance.
